Search
Search
Close this search box.

Phytovista Laboratories positioned to support CBD industry with testing

Home » Phytovista Laboratories positioned to support CBD industry with testing

Estimated reading time: 2 minutes

Phytovista Laboratories has been given an extension to its ISO 17025 UKAS accreditation.

Goodbody Health Group has announced its subsidiary Phytovista Laboratories has been given an extension to its accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs (ACMD) Guidance.

The ISO 17025 UKAS accreditation shows that a lab has adequate quality management systems and is able to provide reliable testing and calibration results.  

Read more: ACMD releases new advice on THC levels in consumer CBD products

Executive chairman, Geremy Thomas, stated: “This is another example to show how we as a group not only lead the way in supplying the best quality products but also continue to support the whole CBD industry to put quality and compliance first.”

The Government Chemist highlighted the need for advanced testing for CBD products in its work with the ACMD for the recently published CBD consumer advice. The advice is enabling the UK to lead the way in creating a fully regulated Novel Food consumer CBD market, facilitating consumer choice and confidence.

Advanced testing methodology is desirable to give the required sensitivity and selectivity to reliably detect traces of residues of controlled cannabinoids in consumer CBD products.

Read more: Industry responds to new ACMD CBD product advice

Phytovista Laboratories is one of a very small number accredited for this type of testing.

Goodbody Health Group stated that PhytoVista laboratories is now ideally positioned to help CBD companies achieve compliance by providing data in accordance with the ACMD guidance on acceptable levels of controlled cannabinoids in consumer products.

[activecampaign form=31]

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?